These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 31352603)

  • 1. Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
    Strang J; McDonald R; Campbell G; Degenhardt L; Nielsen S; Ritter A; Dale O
    Drugs; 2019 Sep; 79(13):1395-1418. PubMed ID: 31352603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact.
    Strang J
    Eur Addict Res; 2022; 28(3):161-175. PubMed ID: 34963112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths.
    Strang J
    Addiction; 2015 Jul; 110 Suppl 2():27-35. PubMed ID: 26042565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interest of take-home naloxone for opioid overdose].
    Frauger E; Kheloufi F; Boucherie Q; Monzon E; Jupin L; Richard N; Mallaret M; Micallef J
    Therapie; 2018 Dec; 73(6):511-520. PubMed ID: 30049569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids.
    Dahan A; Franko TS; Carroll JW; Craig DS; Crow C; Galinkin JL; Garrity JC; Peterson J; Rausch DB
    Front Public Health; 2024; 12():1346109. PubMed ID: 38481848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
    Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
    Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid education and nasal naloxone rescue kits in the emergency department.
    Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
    West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.
    Roxburgh A; Hall WD; Gisev N; Degenhardt L
    Drug Alcohol Depend; 2019 Dec; 205():107533. PubMed ID: 31704378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.
    McAuley A; Bouttell J; Barnsdale L; Mackay D; Lewsey J; Hunter C; Robinson M
    Addiction; 2017 Feb; 112(2):301-308. PubMed ID: 27614084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
    Wheeler E; Jones TS; Gilbert MK; Davidson PJ;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):631-5. PubMed ID: 26086633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.
    McDonald R; Strang J
    Addiction; 2016 Jul; 111(7):1177-87. PubMed ID: 27028542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Take-Home Naloxone and the Need for a Publicly Funded Naloxone Supply.
    Kim HS; Aks SE
    J Addict Med; 2022 Jan-Feb 01; 16(1):1-3. PubMed ID: 33534277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Innovative Model for Naloxone Use Within an OTP Setting: A Prospective Cohort Study.
    Katzman JG; Takeda MY; Bhatt SR; Moya Balasch M; Greenberg N; Yonas H
    J Addict Med; 2018; 12(2):113-118. PubMed ID: 29227321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.